SHANGHAI FUDAN-ZHANGJIANG BIO-PHARMACEUTICAL CO.,LTD.

Andere talen Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Aandelen

1349

CNE1000000W4

Beurs gesloten - Hong Kong S.E. Andere beurzen 09:57:42 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,12 ^HKD	+0,47%		+1,44%	-16,86%

26/02	Winst Fudan-Zhangjiang Bio's 2023 daalt	MT
23/02	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Shanghai Fudan-Zhangjiang Buys Structured Deposits Worth 200 Million Yuan	22/04
Fudan-Zhangjiang Bio Sees Profit, Revenue Drop in 2023	01/04
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Proposes Final Ordinary Dividend for the Year Ended December 31, 2023, Payable on August 26, 2024	28/03
Fudan-Zhangjiang Bio's 2023 Profit Falls	26/02
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Fudan-Zhangjiang Bio-Pharmaceutical to Subscribe for Deposit Products Worth 357 Million Yuan	04/01
Fudan-Zhangjiang Invests 357 Million Yuan in Ping An Bank Structured Deposit Products	03/01
Fudan-Zhangjiang Unit's Clinical Trial Application for Glioma Visualization Agent Accepted in China	27/12
Chinese Regulator Accepts Fudan-Zhangjiang Bio-Pharmaceutical's Application for Bladder Cancer Visualization Drug Trial	18/12
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Application	18/12
Chinese Regulator NMPA Grants Acceptance Notice for Shanghai Fudan-Zhangjiang's Investigational Drug	13/11
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug	13/11
Fudan-Zhangjiang Bio-Pharmaceutical's Cancer Drug Passes Chinese Regulator’s Consistency Evaluation	08/11
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Notification of Approval for Supplementary Drug Application	08/11
Fudan-Zhangjiang's Profit Drops 70.5% in Q3	31-10-23
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30-10-23
Moderate to Severe Inflammatory Acne Vulgaris Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	27-10-23
Fudan-Zhangjiang Bio Gets Nod for Cancer Drug Trial	23-10-23
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issued by the National Medical Products Administration of the PRC	20-10-23
Fudan-Zhangjiang Bio Puchases Structured Deposit Products	12-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Aandelen

1349

CNE1000000W4

Andere talen

Filters